Novavax (NASDAQ:NVAX) is a leading player in the field of recombinant vaccines. Using its proprietary technology platform, the company is developing vaccines comprising of protein nanoparticles capable of inducing a strong immune response from patients.
Based on impending result from Phase 3 trial, Prepare, believe that Novavax can prove to be a solid investment opportunity in 2017.
RSV F Vaccine for infants via maternal immunization is a robust short-term growth driver for Novavax
David S. Brown Enterprises has bolstered its Retail Leasing team with the recent hiring of Michael Gosnell
Kennedy Krieger Institute has announced the appointment of Dr. John Campo as Vice President of Psychiatric Services
Pessin Katz Law is pleased to announce that Attorney Adam E. Konstas has been elected to Member
Knollwood, the premier life plan community of choice for those 62 and better in NW Washington, D.C., known for
Editor in Chief, Warfield Digital
Connect
Independent Consultant
Connect
President of Lawrence Howard & Associates
Connect
Partner at Womble Carlyle, LLP
Connect
Owner at Develop DC
Connect
Stinson Marketing Group
Connect
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
